You just read:

Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints

News provided by

Merck Canada Inc.

Jun 10, 2015, 08:30 ET